Chemomab Therapeutics (CMMB) EPS (Diluted) Growth (1y) (2018 - 2025)
Chemomab Therapeutics (CMMB) EPS (Diluted) Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 36.94% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17,091.12% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 61.58% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.16% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 96.09% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | 366.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 366.99% |
| Sep 30, 2025 | -68.88% |
| Dec 31, 2024 | 7,223,623.74% |
| Sep 30, 2024 | -35.60% |
| Jun 30, 2024 | -64.39% |
| Mar 31, 2024 | -58.24% |
| Dec 31, 2023 | -59.90% |
| Sep 30, 2023 | -46.47% |
| Jun 30, 2023 | 11.76% |
| Mar 31, 2023 | 276.15% |
| Dec 31, 2022 | 249.37% |
| Sep 30, 2022 | 371.26% |
| Jun 30, 2022 | 349.03% |
| Mar 31, 2022 | 96.96% |
| Dec 31, 2021 | 99.12% |
| Sep 30, 2021 | 98.77% |
| Jun 30, 2021 | 97.25% |
| Mar 31, 2021 | -0.53% |
| Dec 31, 2020 | 89.94% |
| Sep 30, 2020 | -569,634.88% |